Inovio Pharmaceuticals' Market-Leading Intellectual Property Recognized by MDB Capital Award
BLUE BELL, Pa., May 12, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that MDB Capital Group has recognized Inovio with its CLARUS Award, given annually to publicly traded companies possessing market-changing intellectually property (IP) assets. The award was presented at the second annual Bright Lights Conference in New York City, a meeting that provides institutional investors with a venue to discover the largely unrecognized value of intellectual property.
Christopher A. Marlett, CEO of MDB Capital Group, said, "Inovio Pharmaceuticals was the top company in its industry with the highest 'Tech Score' and number of patent grants, and we are honored to recognize their achievements in driving IP as an asset class and the impact they are making on innovation in America."
MDB's "Tech Score" measures the industry impact of a company's patents, as it is an indicator of a company's competitive position. It is based upon an analysis of the citation ratios of a company's patents relative to its peer group.
Inovio's DNA vaccine pipeline and proprietary delivery technology were selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property. Inovio is one of 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by MDB.
Dr. J. Joseph Kim, Inovio's president and CEO, said: "Intellectual property is the lifeblood of medical innovation and Inovio is proud to be recognized for its preeminent patent estate for our pipeline of DNA vaccines and our innovative vaccine delivery technology."